Advances with microRNAs in Parkinson’s disease research
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is the second-most common age-dependent neurodegenerative disorder and is caused by severe degeneration of dopaminergic neurons in the substantia nigra pars compacta. Unfortunately, current treatment only targets symptoms and involves dopamine replacement therapy, which does not counteract progressive degeneration. MicroRNAs (miRNAs) are a class of small RNA molecules implicated in post-transcriptional regulation of gene expression during development. Recent studies show that miRNAs are playing an important role in the pathophysiology of PD. miRNA-based therapy is a powerful tool with which to study gene function, investigate the mechanism of the disease, and validate drug targets. In this review, we focus on the recent advances of the use of miRNAs in the pathogenesis of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bushati, N., & Cohen, S. M. (2007) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.23.090506.123406 · Cited by 2,750
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024 · cited 16×
“2-27 will cause autosomal recessive juvenile parkinsonism (AR-JP), one of the most common familial forms of PD. 53 It has been reported that parkin participates in the proteasome-mediated degradation as a ubiquitin-protein ligase collaborating with the ubiquitin-conjugating enzyme UbcH7.”
InfluentialLNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589 · cited 2×
“Another example is of modified locked nucleic acids anti-miRs that were designed specifically against miR-122, an abundant liver-specific miRNA.(102,103) This approach has also been successfully used to reduce the amount of miR122 without showing any toxicity in nonhuman primates”
The Widespread Impact of Mammalian MicroRNAs on mRNA Repression and Evolution
Farh, K. K.-H., Grimson, A., Jan, C., Lewis, B. P., Johnston, W. K., Lim, L. P., Burge, C. B., & Bartel, D. P. (2005) · Science · doi:10.1126/science.1121158 · Cited by 1,484
A MicroRNA Feedback Circuit in Midbrain Dopamine Neurons
Kim, J., Inoue, K., Ishii, J., Vanti, W. B., Voronov, S. V., Murchison, E., Hannon, G., & Abeliovich, A. (2007) · Science · doi:10.1126/science.1140481 · Cited by 1,187
Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., Kauppinen, S., Delacourte, A., & De Strooper, B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710263105 · Cited by 1,183
Repression of α-synuclein expression and toxicity by microRNA-7
Junn, E., Lee, K.-W., Jeong, B. S., Chan, T. W., Im, J.-Y., & Mouradian, M. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906277106 · Cited by 655
MicroRNA-Mediated Control of Oligodendrocyte Differentiation
Zhao, X., He, X., Han, X., Yu, Y., Ye, F., Chen, Y., Hoang, T., Xu, X., Mi, Q.-S., Xin, M., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.02.018 · Cited by 508
Alterations of the microRNA network cause neurodegenerative disease
Hébert, S. S., & De Strooper, B. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.12.003 · Cited by 452 · cited 1×
“The expression of one of these miRNAs, miR-133b, has been found to be significantly deficient in the midbrain of PD patient samples compared to controls.(70) In addition, miR-133b appears to function as a negative regulator of dopaminergic neuron development, suggesting a direct link to dopamine homeostasis.”
Conditional Loss of Dicer Disrupts Cellular and Tissue Morphogenesis in the Cortex and Hippocampus
Davis, T. H., Cuellar, T. L., Koch, S. M., Barker, A. J., Harfe, B. D., McManus, M. T., & Ullian, E. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4815-07.2008 · Cited by 447 · cited 2×
“Human brain samples with the miR-433 SNP demonstrated upregulation of both FGF20 and α-synuclein.(84) Thus, it is predicted that elevated FGF20 might predispose to PD through long-term upregulation of α-synuclein and further enhance neurogenesis early in life, but also create chronic Pitx3 Negative feedback loop”
Cited by
Balancing mTOR Signaling and Autophagy in the Treatment of Parkinson’s Disease
Zhu, Z., Yang, C., Iyaswamy, A., Krishnamoorthi, S., Sreenivasmurthy, S. G., Liu, J., Wang, Z., Tong, B. C.-K., Song, J., Lu, J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030728 · Cited by 263
Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease
Ding, H., Huang, Z., Chen, M., Wang, C., Chen, X., Chen, J., & Zhang, J. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.11.014 · Cited by 172
Briggs, C. E., Wang, Y., Kong, B., Woo, T.-U. W., Iyer, L. K., & Sonntag, K. C. (2015) · Brain Research · doi:10.1016/j.brainres.2015.05.021 · Cited by 113
“Several studies have indicated associations of miRNAs with some aspects of PD pathology (summarized in (Heman-Ackah et al., 2013; Ma et al., 2013; Wong and Nass, 2012)).”
BackgroundSun, S., Han, X., Li, X., Song, Q., Lu, M., Jia, M., Ding, J., & Hu, G. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00381 · Cited by 77
Mao, H., & Ding, L. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7853 · Cited by 15
Metadata
- Authors
- Yuan, W., Ma, L., Liangming Wei, L., Wu, F., Hu, Z., & Liu, Z.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2013-10
- Volume
- 7
- Pages
- 1103
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2093309015
- Cited by
- 48
- References
- 14
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances with microRNAs in Parkinson’s disease research. https://app.cochat.ai/papers/10.2147/dddt.s48500
- The paper
- Yuan, W., Ma, L., Liangming Wei, L., Wu, F., Hu, Z., & Liu, Z. (2013). Advances with microRNAs in Parkinson’s disease research. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s48500
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.